Abstract | PURPOSE: EXPERIMENTAL DESIGN: Metastatic tumors from ASPS and CCS patients were resected, processed to single-cell suspensions, transduced with a replication-defective adenoviral vector encoding GM-CSF, and irradiated. Immunizations were administered subcutaneously and intradermally weekly three times and then every other week. RESULTS:
Vaccines were successfully manufactured for 11 of the 12 enrolled patients. Eleven subjects received from three to 13 immunizations. Toxicities were restricted to grade 1-2 skin reactions at inoculation sites. Vaccination elicited local dendritic cell infiltrates and stimulated T cell-mediated delayed-type hypersensitivity reactions to irradiated, autologous tumor cells. Antibody responses to tissue-type plasminogen activator ( tTPA) and angiopoietins-1/2 were detected. Tumor biopsies showed programmed death-1 (PD-1)-positive CD8(+) T cells in association with PD ligand-1 (PD-L1)-expressing sarcoma cells. No tumor regressions were observed. CONCLUSIONS: Vaccination with irradiated, GM-CSF-secreting autologous sarcoma cell vaccines is feasible, safe, and biologically active. Concurrent targeting of angiogenic cytokines and antagonism of the PD-1-negative regulatory pathway might intensify immune-mediated tumor destruction.
|
Authors | John M Goldberg, David E Fisher, George D Demetri, Donna Neuberg, Stephen A Allsop, Catia Fonseca, Yukoh Nakazaki, David Nemer, Chandrajit P Raut, Suzanne George, Jeffrey A Morgan, Andrew J Wagner, Gordon J Freeman, Jerome Ritz, Cecilia Lezcano, Martin Mihm, Christine Canning, F Stephen Hodi, Glenn Dranoff |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 21
Issue 14
Pg. 3178-86
(Jul 15 2015)
ISSN: 1557-3265 [Electronic] United States |
PMID | 25805798
(Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | ©2015 American Association for Cancer Research. |
Chemical References |
- Cancer Vaccines
- Granulocyte-Macrophage Colony-Stimulating Factor
|
Topics |
- Adolescent
- Adult
- Cancer Vaccines
(immunology, therapeutic use)
- Child
- Enzyme-Linked Immunosorbent Assay
- Female
- Granulocyte-Macrophage Colony-Stimulating Factor
(immunology, metabolism)
- Humans
- Male
- Middle Aged
- Sarcoma, Alveolar Soft Part
(therapy)
- Sarcoma, Clear Cell
(therapy)
- Soft Tissue Neoplasms
(therapy)
- Young Adult
|